IL17A and psoriasis: A recent study on treatment response to the IL-17 A antibody Secukinumab in psoriasis patients demonstrated that ERAP2 deficient patients (as indicated by carrying the rs2248374 G/G genotype) had a 6-fold increased risk of treatment failure compared to ERAP2 proficient patients [28].